Combination Urothelial Cancer Treatment Nearly Doubles Patient Survival in International Trial

Combining the anticancer drugs enfortumab vedotin and pembrolizumab (EV+P) led to significantly improved survival rates among patients with advanced urothelial cancer (the most common type of bladder cancer) compared with standard chemotherapy, according to results of a large international clinical trial involving 185 sites, including the Johns Hopkins Kimmel Cancer Center’s Greenberg Bladder Cancer Institute, in 25 countries.

Promising Approach to Urinary Bladder Tissue Regeneration

Scientists from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago were able to regenerate functional urinary bladder tissue in a rodent model using human bone marrow derived stem and progenitor cells. Their findings, published in Scientific Reports, offer great promise to children suffering from end stage bladder dysfunction, for whom surgery carries significant risks.

Baylor Scott & White Medical Center – Temple Performs 1000th HoLEP Procedure That Improves Men’s Quality of Life

In mid-October, Baylor Scott & White Medical Center – Temple conducted its 1000th holmium laser enucleation of the prostate (HoLEP), a minimally invasive procedure that can address benign prostatic hyperplasia (BPH). BPH can prevent the bladder from emptying properly and could lead to kidney damage or failure. It also impacts quality of life in about one third of men older than 50 years old.